Bariatric Surgery Endocrine Implications

Metabolic and bariatric surgery changes more than stomach capacity. It changes how quickly nutrients reach the intestine, alters gut-hormone signaling, reduces caloric intake, and often improves insulin sensitivity before major weight loss occurs. A sleeve gastrectomy removes much of the stomach and restricts intake. Roux-en-Y gastric bypass creates a small gastric pouch and routes food past the duodenum and part of the proximal jejunum. The bypassed segments normally contribute to absorption of iron, calcium, and some medications. The more anatomy and absorption are altered, the more carefully the team must reassess nutrition, glucose-lowering therapy, and oral medications. After surgery, nutrients may reach the distal small intestine more quickly. This stimulates incretin hormones, including glucagon-like peptide-1, which can increase insulin secretion when glucose is present and improve postprandial glucose control. Caloric restriction and later weight loss further reduce insulin resistance. That rapid metabolic improvement creates a safety issue: a diabetes regimen that was appropriate before surgery can cause hypoglycemia afterward. A patient does not need dramatic weight loss before insulin or a sulfonylurea becomes excessive.